Menu
close
Menu
close
Menu
close

The latest from Magnitude Biosciences

A fully-fledged pre-clinical contract services provider. 
Here’s what we’ve been up to along the way!

24 March 2022
Ageing drug discovery biotech sees exciting early in vivo data for lead compound
Holly Winskell
No Comments

Five Alarm Bio works with Magnitude Biosciences to develop therapeutics for age-related disease.

Read More
21 March 2022
Case Study: Measuring efficacy to slow ageing for drug discovery biotech Five Alarm Bio
Holly Winskell
No Comments

Five Alarm Bio, a UK drug discovery startup focussing on the underlying mechanisms of ageing to develop therapeutics for age-related disease, works with Magnitude Biosciences to test their compound, FAB001, to test their hypothesis on the nature of ageing.

Read More
10 February 2022
Tiny Worms- Experiments Fast
Holly Winskell
No Comments

David Weinkove, CEO of Magnitude Biosciences joins New Matter

Read More
31 January 2022
Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing
Holly Winskell
No Comments

The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing researcher and entrepreneur David Weinkove, Associate Professor at the Department of Biosciences, Durham University and CEO of Magnitude Biosciences Ltd.

Read More
18 November 2021
Case Study: Michelin & Magnitude Biosciences
Holly Winskell
No Comments

Michelin, a Fortune 500 consumer good manufacturing company and the global leader in tyre manufacturing, works with Magnitude Biosciences for a sustainable, ethical solution for whole organism toxicity testing.

Read More
8 November 2021
ELRIG Drug Discovery 2021
indigo
No Comments

Take a look at our Poster from ELRIG Drug Discovery 2021: Automated Monitoring of C. elegans Movement for Neurodegeneration and Ageing.

Read More
Blog Post
Ageing drug discovery biotech sees exciting early in vivo data for lead compound
Press Release
Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing
newsPublication
Frontiers in Aging: Applying C. elegans to industrial drug discovery
Press Release
Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting...
Press Release
Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand
Blog Post
Could C. elegans be the key to slowing ageing?
Blog Post
Frontiers in Longevity: How do we slow human ageing?
Blog Post
Translating groundbreaking drug development ideas into therapies with worms: takeaways from the joint ELRIG and British Pharmacological Society 2021 meeting
Blog Post
Unlocking the microbiome as a target for drug discovery using C. elegans
news
Magnitude Biosciences recognised in Developed in Durham as local success story
Ageing drug discovery biotech sees exciting early in vivo data for lead compound
Holly Winskell Mar 24, 2022
Five Alarm Bio works with Magnitude Biosciences to develop therapeutics for age-related disease. ...Read More
Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing
Holly Winskell Jan 31, 2022
The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing res...Read More
Frontiers in Aging: Applying C. elegans to industrial drug discovery
Mira Nair Oct 28, 2021
Just published in Frontiers in Aging: Applying C. elegans to industrial drug discovery...Read More
,
Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms
Holly Winskell Aug 23, 2021
The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims ...Read More
Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand
Holly Winskell Jul 29, 2021
Hannah Raddings (right) and Alana Mullins (centre) with Magnitude Biosciences Head of Experiments Mi...Read More
Could C. elegans be the key to slowing ageing?
Holly Winskell Jul 26, 2021
Originally published in Health Tech World: https://www.htworld.co.uk/interviews/could-c-elegans-be-t...Read More
Frontiers in Longevity: How do we slow human ageing?
Holly Winskell Jul 19, 2021
How do we slow the process of Ageing? David Weinkove discusses learnings from the Clubhouse event "T...Read More
Translating groundbreaking drug development ideas into therapies with worms: takeaways from the joint ELRIG and British Pharmacological Society 2021 meeting
Holly Winskell Jul 9, 2021
Some fascinating ideas came out of the Translating Ideas Into Therapies meeting held June 30-July 1 ...Read More
Unlocking the microbiome as a target for drug discovery using C. elegans
Holly Winskell Jul 8, 2021
The human microbiome holds great promise for modern medicine but is still largely a mystery to scie...Read More
Magnitude Biosciences recognised in Developed in Durham as local success story
Holly Winskell Jun 7, 2021
Magnitude Biosciences has been recognised by Developed in Durham....Read More
Magnitude Biosciences to attend Translating Ideas Into Therapies 2021 and the International C. elegans Conference in June 2021
Holly Winskell Jun 3, 2021
June 2021 marks an exciting month as we see some of our C. elegans thought leaders speaking at key e...Read More
Holly and Maggie
A child, a worm, and a new era of drug discovery
Mira Nair May 27, 2021
This article will tell the story of how C. elegans enabled a life-changing effects drug therapy for ...Read More
The Magnitude Biosciences team
Magnitude Biosciences launches new website
Mira Nair May 22, 2021
Magnitude Biosciences, the world’s leading C. elegans Contract Research Organisation (CRO) and com...Read More
Magnitude Biosciences secures its second round of funding to support its pre-clinical research services
Magnitude Bioscience Apr 16, 2021
Biosciences spinout secures six-figure funding to create new North East jobs A spinout enterprise fr...Read More
Magnitude Biosciences will be pleased to attend Vermidi 23 online, co-ordinated from the Sorbonne, Paris.
Magnitude Bioscience Apr 16, 2021
Magnitude Biosciences will be pleased to attend Vermidi 23 online, co-ordinated from the Sorbonne, P...Read More
Magnitude Biosciences announces new hires to support continued growth
Magnitude Bioscience Apr 7, 2021
Durham, UK - March 2021 Magnitude Biosciences, a spin-out from Durham University and the leading con...Read More
Magnitude Biosciences secures UK government Future Fund to expand its workforce.
Magnitude Bioscience Mar 5, 2021
Durham, UK - August 2020 Research into new medicines is needed more than ever, but research labs acr...Read More
Magnitude Biosciences' new COVID-19 compatible laboratory is fully operational and we are ready to support your research
Magnitude Bioscience Mar 5, 2021
Magnitude Biosciences moves its unique COVID-19 compatibletechnology to a new lab at NETPark in Sedg...Read More
Magnitude Biosciences will be presenting at the online European Worm Meeting.
Magnitude Bioscience Mar 5, 2021
Magnitude Biosciences will be presenting at the online European Worm Meeting....Read More
Magnitude Biosciences now offers Transgenic Services after acquiring Invermis Ltd.
Magnitude Bioscience Mar 5, 2021
Magnitude Biosciences now offers Transgenic Services after acquiring Invermis Ltd. ...Read More
The Magnitude Biosciences team
Magnitude Biosciences enters the world of Contract Research Services, as a spin-out from Durham University, UK
Magnitude Bioscience Mar 5, 2021
Magnitude Biosciences enters the world of Contract Research Services, as a spin-out from Durham Univ...Read More
Ageing drug discovery biotech sees exciting early in vivo data for lead compound
Holly Winskell Mar 24, 2022
Five Alarm Bio works with Magnitude Biosciences to develop therapeutics for age-related disease. ...Read More
Case Study: Measuring efficacy to slow ageing for drug discovery biotech Five Alarm Bio
Holly Winskell Mar 21, 2022
Five Alarm Bio, a UK drug discovery startup focussing on the underlying mechanisms of ageing to deve...Read More
Tiny Worms- Experiments Fast
Holly Winskell Feb 10, 2022
David Weinkove, CEO of Magnitude Biosciences joins New Matter ...Read More
Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing
Holly Winskell Jan 31, 2022
The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing res...Read More
Case Study: Michelin & Magnitude Biosciences
Holly Winskell Nov 18, 2021
Michelin, a Fortune 500 consumer good manufacturing company and the global leader in tyre manufactur...Read More
ELRIG Drug Discovery 2021
indigo Nov 8, 2021
Take a look at our Poster from ELRIG Drug Discovery 2021: Automated Monitoring of C. elegans&nb...Read More
Fat Staining Assay Datasheet
indigo Nov 8, 2021
Determine whether caloric restriction could be involved in your test compound's mode of action. ...Read More
Frontiers in Aging: Applying C. elegans to industrial drug discovery
Mira Nair Oct 28, 2021
Just published in Frontiers in Aging: Applying C. elegans to industrial drug discovery...Read More
,
Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms
Holly Winskell Aug 23, 2021
The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims ...Read More
Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand
Holly Winskell Jul 29, 2021
Hannah Raddings (right) and Alana Mullins (centre) with Magnitude Biosciences Head of Experiments Mi...Read More
Could C. elegans be the key to slowing ageing?
Holly Winskell Jul 26, 2021
Originally published in Health Tech World: https://www.htworld.co.uk/interviews/could-c-elegans-be-t...Read More
Frontiers in Longevity: How do we slow human ageing?
Holly Winskell Jul 19, 2021
How do we slow the process of Ageing? David Weinkove discusses learnings from the Clubhouse event "T...Read More
C. elegans to accelerate industrial drug discovery and address the costs and challenges of early preclinical research
Holly Winskell Jul 15, 2021
Magnitude Bioscience CEO, David Weinkove, discusses the application of C. elegans to accelerate the ...Read More
Translating groundbreaking drug development ideas into therapies with worms: takeaways from the joint ELRIG and British Pharmacological Society 2021 meeting
Holly Winskell Jul 9, 2021
Some fascinating ideas came out of the Translating Ideas Into Therapies meeting held June 30-July 1 ...Read More
Unlocking the microbiome as a target for drug discovery using C. elegans
Holly Winskell Jul 8, 2021
The human microbiome holds great promise for modern medicine but is still largely a mystery to scie...Read More
Developing a System to Quantify Efficacy of Neurodegeneration Therapeutics Using Automated Monitoring of C. elegans
Holly Winskell Jul 5, 2021
Check out our poster showing how we can quantify the efficacy of neurodegeneration models...Read More
C. elegans mobility decline
Magnitude Bioscience Jun 21, 2021
This video shows an automated method to quantify that decline developed by Magnitude Biosciences whi...Read More
Neuronal SKN-1B modulates nutritional signalling pathways and mitochondrial networks to control satiety
Magnitude Bioscience Jun 21, 2021
Neuronal SKN-1B modulates nutritional signalling pathways and mitochondrial networks to control sati...Read More
Chemosensory Neurons Modulate the Response to Oomycete Recognition in Caenorhabditis elegans
Magnitude Bioscience Jun 21, 2021
The Barkoulas Lab, including our own Michael Fasseas , find an Oomycetes recognition response in C....Read More
UK SPINE Recording
Magnitude Bioscience Jun 21, 2021
Our CEO, David Weinkove, discusses the use of C. elegans and how they could be used in the...Read More
Microbiome SIG Webinar Series
Magnitude Bioscience Jun 21, 2021
Our CEO, Dr. David Weinkove, explains how healthspan readouts can be used to understand mechanisms i...Read More
Automated Imaging of C. elegans for Ageing, Neurodegeneration and Behaviour
Magnitude Bioscience Jun 21, 2021
How large scale non-invasive imaging of C. elegans to enable reliable measurement of Agein...Read More
C. elegans Automated Imaging Platform
Magnitude Bioscience Jun 21, 2021
Magnitude Biosciences presentation from ELRIG online 2020 on the use of C. elegans in pre-...Read More
C. elegans Automated Imaging in Drug Discovery
Magnitude Bioscience Jun 21, 2021
De-risking drug candidates ahead of rodent studies with a non-mammalian model for ageing, neurodegen...Read More
An overview of the use of C. elegans in longevity research including the genetic manipulation of animals.
Magnitude Bioscience Jun 21, 2021
An overview of the use of C. elegans in longevity research including the genetic manipulat...Read More
Magnitude Biosciences recognised in Developed in Durham as local success story
Holly Winskell Jun 7, 2021
Magnitude Biosciences has been recognised by Developed in Durham....Read More
Magnitude Biosciences to attend Translating Ideas Into Therapies 2021 and the International C. elegans Conference in June 2021
Holly Winskell Jun 3, 2021
June 2021 marks an exciting month as we see some of our C. elegans thought leaders speaking at key e...Read More
Holly and Maggie
A child, a worm, and a new era of drug discovery
Mira Nair May 27, 2021
This article will tell the story of how C. elegans enabled a life-changing effects drug therapy for ...Read More
The Magnitude Biosciences team
Magnitude Biosciences launches new website
Mira Nair May 22, 2021
Magnitude Biosciences, the world’s leading C. elegans Contract Research Organisation (CRO) and com...Read More
Magnitude Biosciences secures its second round of funding to support its pre-clinical research services
Magnitude Bioscience Apr 16, 2021
Biosciences spinout secures six-figure funding to create new North East jobs A spinout enterprise fr...Read More
Magnitude Biosciences will be pleased to attend Vermidi 23 online, co-ordinated from the Sorbonne, Paris.
Magnitude Bioscience Apr 16, 2021
Magnitude Biosciences will be pleased to attend Vermidi 23 online, co-ordinated from the Sorbonne, P...Read More
Magnitude Biosciences announces new hires to support continued growth
Magnitude Bioscience Apr 7, 2021
Durham, UK - March 2021 Magnitude Biosciences, a spin-out from Durham University and the leading con...Read More
Magnitude Biosciences secures UK government Future Fund to expand its workforce.
Magnitude Bioscience Mar 5, 2021
Durham, UK - August 2020 Research into new medicines is needed more than ever, but research labs acr...Read More
Magnitude Biosciences' new COVID-19 compatible laboratory is fully operational and we are ready to support your research
Magnitude Bioscience Mar 5, 2021
Magnitude Biosciences moves its unique COVID-19 compatibletechnology to a new lab at NETPark in Sedg...Read More
Magnitude Biosciences will be presenting at the online European Worm Meeting.
Magnitude Bioscience Mar 5, 2021
Magnitude Biosciences will be presenting at the online European Worm Meeting....Read More
Magnitude Biosciences now offers Transgenic Services after acquiring Invermis Ltd.
Magnitude Bioscience Mar 5, 2021
Magnitude Biosciences now offers Transgenic Services after acquiring Invermis Ltd. ...Read More
The Magnitude Biosciences team
Magnitude Biosciences enters the world of Contract Research Services, as a spin-out from Durham University, UK
Magnitude Bioscience Mar 5, 2021
Magnitude Biosciences enters the world of Contract Research Services, as a spin-out from Durham Univ...Read More

CONTACT US

Get in touch today to find out how we can 
support you to accelerate your research

CONTACT US

Get in touch today to find out how we can 
support you to accelerate your research
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram